Valeant, now Bausch Health, paid $1 billon in 2015 for Sprout Pharmaceuticals’ female libido drug Addyi, only to sell it back in 2017. Now as the drug is still nowhere near the blockbuster status ...

Addyi, sometimes referred to as “female Viagra,” is now approved for use to treat low sex drive in postmenopausal women. MoMo Productions/Getty Images The Food and Drug Administration (FDA) expanded ...

(Reuters) - Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire ...

The Food and Drug Administration (FDA) is considering possible regulatory action, due to a spike in reported adverse events associated with the drug Addyi (flibanserin), which is indicated for ...

The drug, which is injected by patients, will join the daily pill Addyi as the only two options on the market to treat low libido in women Rachel DeSantis is a senior writer on the music team at ...

Two weeks ago, the Food and Drug Administration (FDA) approved Vyleesi (bremelanotide), a first-in-class injectable treatment indicated for hypoactive sexual desire disorder (HSDD) in pre-menopausal ...

He pops his little blue pill to treat erectile dysfunction. She injects her thigh with the antidote for low desire. And soon it's off to bed, with some help from modern medicine. That's the scenario ...

Pop culturally, female sexual desire is treated as the holy grail: oft-sought, oft-imitated, oft-worshipped and oft-misunderstood. But outside of Hollywood writers’ rooms, the holy grail does not ...

The US Food and Drug Administration approved a drug to return sexual desire to some women with low libido, the agency said Friday. The drug, bremelanotide, sold under the brand name Vyleesi by AMAG ...

The Food and Drug Administration approved Vyleesi, a drug for premenopausal women to raise sexual interest. It treats a condition called hypoactive sexual desire disorder that some believe affects ...